drugset / Trial / NCT06990711
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Phase 1
Recruiting
30 enrolled
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI) · collabUniversity of Utah · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens. We are testing the safety and tolerability of the addition of a novel immunosuppressive medication to routine treatment for antibody-mediated rejection. Future studies will be needed to assess efficacy if this study demonstrates safety
Timeline
- Start
- 2025-11-06
- Primary completion
- 2027-12-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 5.5 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | Intravenous |